High-dose Chemotherapy Combined with Peripheral Blood Stem Cell Transplantation for Two Cases with Small-cell Lung Cancer

Two patients with small-cell lung cancer were treated with high-dose intensification therapy combined with peripheral blood stem cell transplantation. Case 1 was a 53 year-old male, who was diagnosed as limited-stage small-cell lung cancer with superior vena cava syndrome. Case 2 was a 55 year-old male, diagnosed as extensive-stage small-cell lung cancer. Both patients achieved partial response (a greater than 90% reduction in tumor size) to conventional-dose induction chemotherapy with cisplatin, carboplatin and etoposide. Peripheral blood stem cells were collected by leukopheresis at a recovery phase of bone marrow function with mobilization by granulocyte-colony stimulating factor following an intensified chemotherapy with cisplatin and etoposide. Thereafter, they were treated with high-dose etoposide (1200 mg/m²) and carboplatin (2, 100mg/body and 3, 000mg/body) combined with peripheral blood stem cell transplantation. Recovery of bone marrow function after peripheral blood stem cell transplantation was seen on day 9 and 13, respectively, and other treatment-related side effects were slight. It is suggested that peripheral blood stem cell transplantation is useful for hematopoietic support after high-dose intensification therapy.